首页 | 本学科首页   官方微博 | 高级检索  
     检索      

EXPRESSION OF IL-2 AND SIL-2R AND ALTERATION OF CELL IMMUNITY IN PATIENTS WITH HYPERTENSIVE CEREBRAL HEMORRHAGE
作者姓名:张越林  邱曙东  师蔚  党小军
作者单位:Medical School of Xi'an Jiaotong University, Xi'an 710061, China.
基金项目:Foundation Item: this work was supported by the Shaanxi Provincial Science and Technology Bureau Science and Technology Innovation (No. 2002K10--G6)
摘    要:Objective To study the expression of interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R), determine the alteration of erythrocytic immunity and T cell subgroup in the blood of outer circulation in patients with hypertensive cerebral hemorrhage so and to probe into the relationship between them, and to explore the clinical significance. Methods Enzyme linked immnunosorbent assay (ELISA) was used to determine the content of IL-2 and slL-2R. The immunoadsorption was employed to examine the erythrocytic immune activity and its regulating function. ( S-P) was used to determine the cell number of CD3 (cluster of differentiation3), CD4 and CD8. Resolts The content of IL-2 in the group with hypertensive cerebral hemorrhage was significantly lower than that in the control group (P〈0.01), and the content of sIL-2R increased. Red blood cell C3b receptor (RBC. C3bR) and RBC immune adherence enhancing factor (RFEB) dropped greatly (P〈0.01), while RBC immune complex rosette (RBC. ICR) and RBC immune adherence inhibiting factor (RFIR) increased greatly. The cell number of CD3 and CD4decreased (P〈0.01) and there was no obvious change in CD8 (P〈 0. 05). Conclusion The decrease of immune function was observed in patients with hypertensive cerebral hemorrhage. The determination of the content of IL-2, sIL- 2R, erythrocytic immunity and the activity of T subgroup has an important clinical significance in the occurrence, development, treatment, and prognosis of hypertensive cerebral hemorrhage.

关 键 词:IL-2  SIL-2R  基因表达  细胞免疫  高血压  脑出血
文章编号:1671-8267(2006)01-0090-04

EXPRESSION OF IL-2 AND SIL-2R AND ALTERATION OF CELL IMMUNITY IN PATIENTS WITH HYPERTENSIVE CEREBRAL HEMORRHAGE
Zhang Yuelin,Qiu Shudong,Shi Wei,Dang Xiaojun.EXPRESSION OF IL-2 AND SIL-2R AND ALTERATION OF CELL IMMUNITY IN PATIENTS WITH HYPERTENSIVE CEREBRAL HEMORRHAGE[J].Academic Journal of Xi’an Jiaotong University,2006,18(1):90-93.
Authors:Zhang Yuelin  Qiu Shudong  Shi Wei  Dang Xiaojun
Abstract:Objective To study the expression of interleukin-2(IL-2), soluble interleukin-2 receptor (sIL-2R), determine the alteration of erythrocytic immunity and T cell subgroup in the blood of outer circulation in patients with hypertensive cerebral hemorrhage so and to probe into the relationship between them, and to explore the clinical significance. Methods Enzyme linked immnunosorbent assay (ELISA) was used to determine the content of IL-2 and sIL-2R. The immunoadsorption was employed to examine the erythrocytic immune activity and its regulating function. Streptavidin-peroxidase(S-P) was used to determine the cell number of CD3 (cluster of differentiation3), CD4 and CD8. Results The content of IL-2 in the group with hypertensive cerebral hemorrhage was significantly lower than that in the control group (P<0.01), and the content of sIL-2R increased. Red blood cell C_ 3b receptor (RBC.C_ 3b R) and RBC immune adherence enhancing factor (RFEB) dropped greatly (P<0.01), while RBC immune complex rosette (RBC.ICR) and RBC immune adherence inhibiting factor (RFIR) increased greatly. The cell number of CD3 and CD4decreased (P<0.01) and there was no obvious change in CD8 (P<0.05). Conclusion The decrease of immune function was observed in patients with hypertensive cerebral hemorrhage. The determination of the content of IL-2, sIL-2R, erythrocytic immunity and the activity of T subgroup has an important clinical significance in the occurrence, development, treatment, and prognosis of hypertensive cerebral hemorrhage.
Keywords:hypertensive cerebral hemorrhage  IL-2  sIL-2R  erythrocyte immunity  T cell subgroup
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号